<DOC>
	<DOCNO>NCT01654861</DOCNO>
	<brief_summary>- The combination gemcitabine HDIVC safe may favorably change clinical course individual patient . - The combination gemcitabine HDIVC synergistic anti-tumor effect see preclinical model , HDIVC create pro-oxidative effect add anti-tumor effect gemcitabine . - The combination gemcitabine HDIVC may improve Progression Free Survival ( PFS ) . - The dosage schema 1.2 g /kg bolus infusion follow low dose 0.3 g / kg infusion may create sustained elevation Vitamin C plasma level increase cytotoxic effect . - The addition HDIVC &amp; oral supplementation Vitamin C standard treatment gemcitabine may improve quality life patient comparison prior treatment start protocol . - CA 19-9 inflammatory marker may show trend patient trial .</brief_summary>
	<brief_title>Safety Efficacy Study Gemcitabine Combined With High Dose Intravenous Vitamin C ( HDIVC ) Patients With Metastatic Adenocarcinoma Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Patient ≥ 18 year age Biopsy proven adenocarcinoma pancreas Evidence metastatic disease Received least 1 prior chemotherapy treatment regimen disease progression May prior chemotherapy regimen include gemcitabine base regimen FOLFIRINOX May participate prior study protocol May prior treatment HDIVC Anticipated survival least 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status = 0,1 , 2 The patient must screen laboratory : ANC ≥ 1,500/mm3 , Hemoglobin &gt; 8g/dL , Platelets ≥ 100,000/mm3 , Total Bilirubin &lt; 1.5mg/dL , Creatinine ≤ 1.5mg/dL , Transaminases &lt; 2.5 x upper limit normal , Urine Uric Acid &lt; 1.000 mg/d , Urine pH &lt; 6 , Urine microscopic negative oxalate ( positive , reflex urinary oxalate &lt; 60mg/d ) , PT INR ≤ 1.5 , unless patient full dose warfarin Glucose6phosphate dehydrogenase deficiency ( G6PD ) normal status via blood test The fluorescent spot test simplest , reliable , sensitive G6PD screening test Willingness undergo central line placement able manage care entry site safely Willingness adhere supplemental oral dose regimen ascorbic acid 500mg take twice daily All nutritional supplement would discontinue duration trial except pancreatic enzyme probiotic Patients must able take food orally peg tube feed Able give consent protocol participation Glucose6phosphate dehydrogenase deficiency ( G6PD ) Renal insufficiency : serum creatinine &gt; 1.5 mg /dl evidence oxalosis urinalysis prior enrollment prior HDIVC infusion Documentation report history kidney stone urinary oxalosis . Comorbid condition would affect survival : congestive heart failure , unstable angina , myocardial infarction within 6 week study , uncontrolled blood sugar &gt; 300 mg / dl , patient know chronic active hepatitis cirrhosis Currently active second malignancy Chronic hemodialysis Iron overload/ Hemochromatosis : Ferritin &gt; 500 ng / ml Wilson 's disease Pregnant lactate female ( pre menopausal female undergo pregnancy test prior administration protocol drug throughout treatment cycle study ) Aspirin use exceed 81 mg per day Acetaminophen use exceed 2 g per day Known brain metastasis Active tobacco smoker Treatment combination HDIVC gemcitabine previously</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>